Rakovina Therapeutics Inc.
RKV.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 239.66% | 247.69% | 172.50% | 74.67% | 41.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 154.27% | 161.25% | 98.06% | 49.66% | 22.26% |
| Operating Income | -154.27% | -161.25% | -98.06% | -49.66% | -22.26% |
| Income Before Tax | -146.07% | -150.00% | -94.13% | -52.88% | -29.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -146.07% | -150.00% | -94.13% | -52.88% | -29.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -146.07% | -150.00% | -94.13% | -52.88% | -29.18% |
| EBIT | -154.27% | -161.25% | -98.06% | -49.66% | -22.26% |
| EBITDA | -187.93% | -202.20% | -125.47% | -63.69% | -28.60% |
| EPS Basic | -26.09% | -38.58% | -31.99% | -27.31% | -19.89% |
| Normalized Basic EPS | -25.59% | -38.09% | -31.45% | -26.83% | -19.88% |
| EPS Diluted | -42.15% | -52.53% | -44.48% | -27.23% | -11.95% |
| Normalized Diluted EPS | -25.59% | -38.09% | -31.45% | -26.83% | -19.88% |
| Average Basic Shares Outstanding | 103.61% | 74.60% | 43.55% | 18.37% | 7.55% |
| Average Diluted Shares Outstanding | 103.61% | 74.60% | 43.55% | 18.37% | 7.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |